证券代码：603222 证券简称：济民健康 公告编号：2026-002 济民健康管理股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 鄂州二院有限 | | 次担保金额） | | | | | --- | --- | --- | --- | --- | --- | | 被担保人名称 公司 | 本次担保金额 9,337.00 万元 | 实际为其提供的 担保余额（不含本 6,826.00 | 万元 | 是否在前期 预计额度内 是 | 本次担保是 否有反担保 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 26,719.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 18.04 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ 每经AI快讯，济民健康12月31日晚间发布公告称，截至2025年12月31日，公司通过集中竞价交易方式 累计回购股份约306万股，占公司总股本的比例为0.58%，购买的最高价为9.75元/股，最低价为5.87元/ 股，已支付的总金额约为2198万元。 ...

格隆汇12月31日丨济民健康(603222.SH)公布，截至2025年12月31日，公司通过集中竞价交易方式累计 回购股份306.05万股，占公司总股本的比例为0.58%，购买的最高价为9.75元/股，最低价为5.87元/股， 已支付的总金额为2198.38万元（不含交易费用）。 ...

二、回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关 规定，公司在回购期间，应当在每个月的前 3 个交易日内公告截至上月末的回购 进展情况，现将公司回购股份进展情况公告如下： 证券代码：603222 证券简称：济民健康 公告编号：2026-001 济民健康管理股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 306.05万股 | | 累计已回购股数占总股本比例 | 0.58% | | 累计已回购金额 | 2,198.38万元 | | 实际回购价格区间 | 5.87元 ...

格隆汇12月31日丨济民健康(603222.SH)公布，截至2025年12月31日，公司通过集中竞价交易方式累计 回购股份306.05万股，占公司总股本的比例为0.58%，购买的最高价为9.75元/股，最低价为5.87元/股， 已支付的总金额为2198.38万元（不含交易费用）。 ...

证券日报网讯 12月29日，济民健康在互动平台回答投资者提问时表示，公司成立新的合资公司核心目 的为公司培育和整合优质标的资产，推动公司产业转型升级，增强公司核心竞争力及可持续发展能力。 （编辑 丛可心） ...

Group 1 - Hubei Jimin Military-Civilian Technology Innovation Co., Ltd. has been established with a registered capital of 600 million yuan [1] - The company's business scope includes integrated circuit design, software development, information system integration services, and information technology consulting services [1] - Jimin Health holds 100% ownership of the newly established company [1]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Core Viewpoint - Jimin Health (603222.SH) has announced the establishment of a joint venture with Hubei Military-Civilian Technology Innovation Co., Ltd., with a registered capital of 600 million RMB [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of 600 million RMB, with Jimin Health contributing 294 million RMB for a 49% stake [1] - Hubei Military-Civilian Technology Innovation Co., Ltd. will contribute 306 million RMB for a 51% stake [1] - Both parties will contribute cash for their respective stakes in the joint venture [1] Group 2: Implementation and Registration - The board of directors of Jimin Health approved the proposal to establish the joint venture during its sixth session's second meeting [1] - The company has completed the establishment of the joint venture and has obtained the registration certificate [1] - The management team has been authorized to handle the implementation of the relevant plans and procedures [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-063 济民健康管理股份有限公司 关于合资公司设立完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、发起设立合资公司的基本情况 二、设立合资公司的进展情况 近日，公司已完成合资公司的设立工作，并取得了注册登记证明文件，相关 信息如下： 1、名称：湖北济民军民科技创新有限公司 2、统一社会信用代码：91420117MAK497JB60 3、类型：其他有限责任公司 4、注册资本：陆亿元 5、法定代表人：贺怡帆 6、成立日期：2025 年 12 月 18 日 7、注册地址: 湖北省武汉市新洲区辛冲街东城社区里闹南路 32 号 8、经营范围：一般项目:技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广；集成电路设计；软件开发；信息系统集成服务；信息技术咨询 服务。(除许可业务外,可自主依法经营法律法规非禁止或限制的项目) 特此公告。 济民健康管理股份有限公司董事会 2025 年 12 月 24 日 2025 年 12 月 12 日，济民健康管理股份 ...